A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

DEST Insider Trading (Destiny Pharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £251,580
Insider Selling (Last 12 Months): GBX 0

Destiny Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Destiny Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Destiny Pharma Share Price & Price History

Current Price: GBX 40
Price Change: +0.30 (1.20%)
As of 08/12/2022 01:00 AM ET

This chart shows the closing price history over time for DEST up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

Destiny Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/27/2021Nick RodgersInsiderBuy2,100£119.80£251,580
4/29/2021Nick RodgersInsiderBuy1,511GBX 149£2,251.39
4/22/2021Nick RodgersInsiderBuy5,000GBX 158£7,900
1/6/2021Nick RodgersInsiderBuy9,000GBX 88£7,920
See Full Table
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for Destiny Pharma (LON:DEST)

Destiny Pharma logo
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More on Destiny Pharma

Today's Range

Now: GBX 40
Low: 40
High: 40.20

50 Day Range

MA: GBX 40.98
Low: 35
High: 47.50

52 Week Range

Now: GBX 40
Low: 35
High: 127

Volume

120,794 shs

Average Volume

45,702 shs

Market Capitalization

£29.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Destiny Pharma?

Destiny Pharma's top insider investors include:
  1. Nick Rodgers (Insider)
Learn More about top insider investors at Destiny Pharma.
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!